Aging will be slowed down with the help of AI - a new discovery

An experimental drug, rentosertib, developed with AI by Insilico Medicine, has shown the ability to influence aging biomarkers. In a 12-week study involving 42 volunteers, those taking the drug saw reductions in biological age indicators across six models. However, the authors emphasize that this does not prove a slowdown in aging or rejuvenation of the body.

An experimental drug, rentosertib, developed by Insilico Medicine using artificial intelligence, has shown the ability to influence biomarkers associated with aging. In a 12-week study involving 42 volunteers, scientists tracked changes in the body using six different models for assessing biological age. Participants who took rentosertib recorded a decrease in biological age indicators, while in the placebo and no-therapy groups, indicators remained largely unchanged or increased. Researchers suggest that the drug's effect may involve multiple aging mechanisms. However, the authors emphasize that improvements in biological clock indicators do not prove actual slowing of aging or rejuvenation of the body. Biological clocks are models that analyze DNA, blood composition, and other parameters, but their accuracy is debated among specialists, and there is no single reliable method for assessing biological age. Rentosertib is in the experimental development stage and requires additional clinical trials to confirm its efficacy and safety. Previously, "Cursor" reported on another AI model for studying age-related changes in the immune system.